In vivo sensitivity to vincristine correlates with length of CR1.

The EFS of NOD/SCID mice was quantified as the time taken for the leukemic population to reach 25% in the peripheral blood, or for the animals to show evidence of leukemia-related morbidity, following the initiation of vincristine treatment (Table 5). Data for length of CR1 are taken from Table 1. Data points are shown for patients whose cells were harvested at diagnosis (open circles) or relapse (closed circles).